Jessica Hopwood

Chief Technical Operations Officer at Proveca Ltd

Jessica Hopwood has extensive work experience in the pharmaceutical industry. Jessica'smost recent role was as the Head of Business Operations at Proveca Ltd, which they started in June 2022. Prior to that, they held the position of Head of Project Management at the same company from July 2021 to June 2022.

Before joining Proveca Ltd, Jessica worked at Ipsen for many years. Jessica'sroles at Ipsen included Interim Director of Strategy and Transformation, Lifecycle Project Manager, CMC Development Project Manager, Technical Project Leader, Technical Specialist 2, Validation Specialist, Analytical Validation Officer, Validation Analyst, and QC Technician. These positions involved various responsibilities such as leading project management initiatives, managing complex projects, coordinating program activities, and overseeing site strategy and transformation programs.

Overall, Jessica's work experience demonstrates their expertise in project management, strategy development, and operations management in the pharmaceutical industry.

Jessica Hopwood obtained a Bachelor's degree in Chemistry/Business Administration from Keele University between 1999 and 2003.

Location

Wrexham, United Kingdom

Links

Previous companies


Org chart


Teams


Offices


Proveca Ltd

Proveca Ltd is a pharmaceutical company specialising in identifying, researching and licensing off-patent medicines with unmet priority health care needs, with a focus on the paediatric market. By developing the necessary formulations and clinical data required to obtain a Paediatric Use Marketing Authorisation (PUMA) these drugs will benefit froma period of 10 years' market protection (8 years of data and market protection plus 2 further years of market protection). In addition, where appropriate, Orphan Drug status (Orphan Drug) will be sought which affords a period of 10 years' market exclusivity to run concurrently.Value will be realised through commercialisation of the licensed medicine or an outright sale of the licence to a larger pharmaceutical company.


Employees

11-50

Links